GI Symposium Pancreatic Cancer Spotlight

Arginine-Depleting Agent Added to Standard Therapy Shows Promise in Pancreatic Cancer

February 09, 2017

The addition of ADI-PEG 20, a pegylated form of an arginine-depleting enzyme, to nab-paclitaxel and gemcitabine has encouraging activity in patients with advanced pancreatic adenocarcinoma while demonstrating minimal additional toxicity over that with cytotoxic therapy alone.

MPC Treatment Costs Lower with Nab-Paclitaxel/Gemcitabine Than FOLFIRINOX

February 08, 2017

Treatment administration and supportive care costs were significantly higher for patients with metastatic pancreatic cancer who were treated with FOLFIRINOX as first-line therapy compared with the combination of nab-paclitaxel and gemcitabine.

Gemcitabine-Free Regimen Passes Test in Metastatic Pancreatic Cancer

February 08, 2017

A gemcitabine-free regimen resulted in numerically better survival compared with a conventional gemcitabine regimen in patients with metastatic pancreatic cancer, results of a randomized trial showed.

Nanoliposomal Irinotecan Regimen Improves OS in Pancreatic Cancer

February 08, 2017

Overall survival was improved and disease progression was slowed in patients with metastatic pancreatic ductal adenocarcinoma when nanoliposomal irinotecan was added to 5-fluorouracil and leucovorin, irrespective of treatment history, a posthoc analysis of a randomized trial showed.

The Role of Minimally Invasive Surgery in Pancreatic Cancer

February 07, 2017

Mark S. Talamonti, MD, clinical professor, NorthShore University HealthSystem, discusses the current and future role of minimally invasive surgery in pancreatic cancer.

A Study of Nivolumab With Nab-Paclitaxel Plus Gemcitabine in Pancreatic Cancer

February 07, 2017

Gabriela Chiorean, MD, professor of medicine, discusses an ongoing phase I study of nivolumab with nab-paclitaxel plus gemcitabine in pancreatic cancer.

Adding Platinum to Standard of Care Improves Response Rate in Stage IV Pancreatic Cancer

January 25, 2017

Adding a platinum to standard gemcitabine and nab-paclitaxel led to impressive responses and overall survival rates in a small pilot trial in patients with stage IV pancreatic cancer.

CCR2 Blockade Holds Clinical Promise in Advanced or Metastatic Pancreatic Cancer

January 25, 2017

CCX872-B, a potent, selective oral inhibitor of CCR2, added to FOLFIRINOX was associated with a tumor control rate of 78% at week 12 in a single-arm study of patients with locally advanced or metastatic pancreatic cancer.

Chemotherapy/Immunotherapy Regimen Active in Treated, Untreated Pancreatic Cancer

January 25, 2017

Encouraging clinical activity with limited toxicity in patients with metastatic pancreatic cancer will lead to further evaluation of nivolumab plus nab-paclitaxel with gemcitabine, investigators reported at the Gastrointestinal Cancers Symposium in San Francisco.